MITO 16 MANGO OV2B

Trial Description: 
A multicenter phase III randomized study with second line chemotherapy plus or minus bevacizumab in patients with platinum sensitive epithelial ovarian cancer recurrence after a bevacizumab/chemotherapy first line
Lead Cooperative Group: 
Participating Groups: 
Disease Site: 
Ovarian
Trial Status: 
Completed
Contact person: